Sino Biological
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
Latest Sino Biological Content
Online Event
Advances in Drug Discovery & Development 2024
This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development, biopharma and biotechnology.
Product News
InDevR and Sino Biological Team Up To Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy
Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields.
Product
Advertisement
CD2-CD58 Axis: Targets in Immune Synapse
Sino Biological offers a wide range of recombinant CD2 and CD58 proteins and antibodies to support elucidating key interactions and pathways and shedding light on potential therapeutic strategies.
Product News
FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer
On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Product News
Sino Biological Finalizes the Acquisition of SignalChem Biotech
Sino Biological, Inc. ("Sino Biological" or the "Company”), has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
Online Event
The Landscape of Cancer Research: Advances in Immuno-oncology 2024
On-Demand
Key advances will be highlighted across the field of immuno-oncology. Hear a cross-section of experts discuss their research with a focus on basic research and a broad range of established and novel immunotherapeutics.
Product News
Therapeutic Potential of CD20 X CD3 Bispecific Antibodies
As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Product
Advertisement
BEST-IN-CLASS Cytokines for BEST Cell Culture
Click here for further information!
Online Event
Cell and Gene Therapy 2024
On-Demand
Explore cutting-edge cell and gene therapies at our online symposium on March 20–21. Experts will discuss cancer immunotherapy, gene therapy vectors, stem cells, and precision oncology research.
Product
Advertisement
3D Organoid Research Solutions
Learn More!
Advertisement
